tetano
Editor, Senior Moderator
Eur J Haematol
. 2023 Jun 8.
doi: 10.1111/ejh.14024. Online ahead of print. Outcomes of COVID-19 hospitalizations in patients with sickle cell disease: A nationwide analysis
Nosakhare Paul Ilerhunmwuwa[SUP] 1 [/SUP], Lawrence Inyang[SUP] 1 [/SUP], Narek Hakobyan[SUP] 1 [/SUP], Mustafa Wasifuddin[SUP] 1 [/SUP], Muhammad Tahir[SUP] 1 [/SUP], Henry Aiwuyo[SUP] 1 [/SUP], Paul Ankah[SUP] 1 [/SUP], Beatrice E Torere[SUP] 2 [/SUP], Uchenna M Amaechi[SUP] 3 [/SUP], Jen Chin Wang[SUP] 4 [/SUP]
Affiliations
Introduction: There is a paucity of data on the outcomes of coronavirus disease 2019 (COVID-19) in patients with sickle cell disease (SCD) in the United States. We examined the outcomes of patients with COVID-19 and SCD.
Methods: We utilized the National Inpatient Sample (NIS) to identify the data of patients diagnosed with COVID-19 and SCD in 2020 using the International Classification of Disease, Tenth Revision codes. In-hospital outcomes (invasive mechanical ventilation and mortality) were compared between SCD and non-SCD groups.
Results: Of the 1 057 550 COVID-19 hospitalizations, 2870 (0.3%) had SCD. The median age of the SCD group was 42 (IQR: 31) vs. 66 (IQR: 23) in the non-SCD group (p < .0001). Patients with SCD were likely to be females (62.02% vs. 37.98%, p < .0001), Blacks (87.81% vs. 12.19%, p < .0001), and in the lowest income quartile (50.62% vs. 11.15%, p < .0001). There was no difference in the outcomes between the two groups. There were increased odds of invasive mechanical ventilation and in-hospital mortality in COVID-19 in Asians, Hispanics, Native Americans, and Blacks (except for in-hospital mortality) compared to Whites.
Conclusion: In-hospital mortality and invasive mechanical ventilation outcomes in SCD are comparable to that in non-SCD patients hospitalized with COVID-19.
Keywords: coronavirus disease 2019; outcomes; sickle cell disease.
. 2023 Jun 8.
doi: 10.1111/ejh.14024. Online ahead of print. Outcomes of COVID-19 hospitalizations in patients with sickle cell disease: A nationwide analysis
Nosakhare Paul Ilerhunmwuwa[SUP] 1 [/SUP], Lawrence Inyang[SUP] 1 [/SUP], Narek Hakobyan[SUP] 1 [/SUP], Mustafa Wasifuddin[SUP] 1 [/SUP], Muhammad Tahir[SUP] 1 [/SUP], Henry Aiwuyo[SUP] 1 [/SUP], Paul Ankah[SUP] 1 [/SUP], Beatrice E Torere[SUP] 2 [/SUP], Uchenna M Amaechi[SUP] 3 [/SUP], Jen Chin Wang[SUP] 4 [/SUP]
Affiliations
- PMID: 37290934
- DOI: 10.1111/ejh.14024
Introduction: There is a paucity of data on the outcomes of coronavirus disease 2019 (COVID-19) in patients with sickle cell disease (SCD) in the United States. We examined the outcomes of patients with COVID-19 and SCD.
Methods: We utilized the National Inpatient Sample (NIS) to identify the data of patients diagnosed with COVID-19 and SCD in 2020 using the International Classification of Disease, Tenth Revision codes. In-hospital outcomes (invasive mechanical ventilation and mortality) were compared between SCD and non-SCD groups.
Results: Of the 1 057 550 COVID-19 hospitalizations, 2870 (0.3%) had SCD. The median age of the SCD group was 42 (IQR: 31) vs. 66 (IQR: 23) in the non-SCD group (p < .0001). Patients with SCD were likely to be females (62.02% vs. 37.98%, p < .0001), Blacks (87.81% vs. 12.19%, p < .0001), and in the lowest income quartile (50.62% vs. 11.15%, p < .0001). There was no difference in the outcomes between the two groups. There were increased odds of invasive mechanical ventilation and in-hospital mortality in COVID-19 in Asians, Hispanics, Native Americans, and Blacks (except for in-hospital mortality) compared to Whites.
Conclusion: In-hospital mortality and invasive mechanical ventilation outcomes in SCD are comparable to that in non-SCD patients hospitalized with COVID-19.
Keywords: coronavirus disease 2019; outcomes; sickle cell disease.